Histone deacetylase inhibitors modulate interleukin 6-dependent CD4 + T cell polarization in vitro and in vivo

Journal of Biological Chemistry

Volumn 289, Issue 9, 2014, Pages 6142-6151

  Glauben, Rainer ^a   Sonnenberg, Elena ^a   Wetzel, Martin ^a   Mascagni, Paolo ^b   Siegmund, Britta ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Italfarmaco SpA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI-INFLAMMATORIES; ANTI-INFLAMMATORY EFFECTS; ANTIPROLIFERATIVE EFFECT; CELL POLARIZATION; CELL SUBPOPULATIONS; HISTONE DEACETYLASE INHIBITOR; HISTONE DEACETYLASES; REGULATORY T CELLS;

ACETYLATION; CELLS; CYTOLOGY; DISEASES; IMMUNOLOGY; POLARIZATION;

T-CELLS;

GIVINOSTAT; HISTONE DEACETYLASE INHIBITOR; INTERLEUKIN 17; INTERLEUKIN 6 RECEPTOR; RETINOID RELATED ORPHAN RECEPTOR GAMMA; STAT3 PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG POTENCY; ENZYME INHIBITION; EXPERIMENTAL COLITIS; FEMALE; HISTONE ACETYLATION; IL6R GENE; IN VITRO STUDY; IN VIVO STUDY; INTERFERON PRODUCTION; LAMINA PROPRIA; MOUSE; NONHUMAN; POLARIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TH17 CELL;

COLITIS; HISTONE DEACETYLASE INHIBITORS; IL-17; IL-6R; INFLAMMATORY BOWEL DISEASE; MACROPHAGES; PROMOTER ACETYLATION; STAT3; T HELPER CELLS;

ANIMALS; COLITIS; FEMALE; GENE EXPRESSION REGULATION; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HYDROXAMIC ACIDS; INTERLEUKIN-17; INTERLEUKIN-6; MICE; MICE, INBRED BALB C; MUCOUS MEMBRANE; NUCLEAR RECEPTOR SUBFAMILY 1, GROUP F, MEMBER 3; PHOSPHORYLATION; RECEPTORS, INTERLEUKIN-6; RNA, MESSENGER; STAT3 TRANSCRIPTION FACTOR; T-LYMPHOCYTES, REGULATORY; TH17 CELLS;

EID: 84896889451     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M113.517599     Document Type: Article

References (53)

1. Kelly, W. K., and Marks, P. A. (2005) Drug insight. Histone deacetylase inhibitors. Development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat. Clin. Pract. Oncol. 2, 150-157 (Pubitemid 40823166)
2. Marks, P., Rifkind, R. A., Richon, V. M., Breslow, R., Miller, T., and Kelly, W. K. (2001) Histone deacetylases and cancer. Causes and therapies. Nat. Rev. Cancer 1, 194-202 (Pubitemid 33741894)
3. Marks, P. A., and Breslow, R. (2007) Dimethyl sulfoxide to vorinostat. Development of this histone deacetylase inhibitor as an anticancer drug. Nat. Biotechnol. 25, 84-90 (Pubitemid 46087907)
4. Krämer, O. H., Baus, D., Knauer, S. K., Stein, S., Jäger, E., Stauber, R. H., Grez, M., Pfitzner, E., and Heinzel, T. (2006) Acetylation of Stat1 modulates NF-κB activity. Genes Dev. 20, 473-485 (Pubitemid 43244401)
5. Glauben, R., Batra, A., Stroh, T., Erben, U., Fedke, I., Lehr, H. A., Leoni, F., Mascagni, P., Dinarello, C. A., Zeitz, M., and Siegmund, B. (2008) Histone deacetylases. Novel targets for prevention of colitis-associated cancer in mice. Gut 57, 613-622 (Pubitemid 351579973)
6. Glauben, R., Batra, A., Fedke, I., Zeitz, M., Lehr, H. A., Leoni, F., Mascagni, P., Fantuzzi, G., Dinarello, C. A., and Siegmund, B. (2006) Histone hyperacetylation is associated with amelioration of experimental colitis in mice. J. Immunol. 176, 5015-5022
7. Leoni, F., Zaliani, A., Bertolini, G., Porro, G., Pagani, P., Pozzi, P., Donà, G., Fossati, G., Sozzani, S., Azam, T., Bufler, P., Fantuzzi, G., Goncharov, I., Kim, S. H., Pomerantz, B. J., Reznikov, L. L., Siegmund, B., Dinarello, C. A., and Mascagni, P. (2002) The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc. Natl. Acad. Sci. U.S.A. 99, 2995-3000 (Pubitemid 34240574)
8. Mishra, N., Reilly, C. M., Brown, D. R., Ruiz, P., and Gilkeson, G. S. (2003) Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. J. Clin. Invest. 111, 539-552 (Pubitemid 36228011)
9. Nishida, K., Komiyama, T., Miyazawa, S., Shen, Z. N., Furumatsu, T., Doi, H., Yoshida, A., Yamana, J., Yamamura, M., Ninomiya, Y., Inoue, H., and Asahara, H. (2004) Histone deacetylase inhibitor suppression of autoantibody-mediated arthritis in mice via regulation of p16INK4a and p21(WAF1/Cip1) expression. Arthritis Rheum. 50, 3365-3376 (Pubitemid 39372015)
10. Tao, R., de Zoeten, E. F., Ozkaynak, E., Chen, C., Wang, L., Porrett, P. M., Li, B., Turka, L. A., Olson, E. N., Greene, M. I., Wells, A. D., and Hancock, W. W. (2007) Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat. Med. 13, 1299-1307 (Pubitemid 350073591)
11. Reddy, P., Sun, Y., Toubai, T., Duran-Struuck, R., Clouthier, S. G., Weisiger, E., Maeda, Y., Tawara, I., Krijanovski, O., Gatza, E., Liu, C., Malter, C., Mascagni, P., Dinarello, C. A., and Ferrara, J. L. (2008) Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice. J. Clin. Invest. 118, 2562-2573 (Pubitemid 351949783)
12. Choi, J. H., Oh, S. W., Kang, M. S., Kwon, H. J., Oh, G. T., and Kim, D. Y. (2005) Trichostatin A attenuates airway inflammation in mouse asthma model. Clin. Exp. Allergy 35, 89-96 (Pubitemid 40188276)
13. Vojinovic, J., Damjanov, N., D'Urzo, C., Furlan, A., Susic, G., Pasic, S., Iagaru, N., Stefan, M., and Dinarello, C. A. (2011) Safety and efficacy of an oral histone deacetylase inhibitor in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 63, 1452-1458
14. Mucida, D., Park, Y., Kim, G., Turovskaya, O., Scott, I., Kronenberg, M., and Cheroutre, H. (2007) Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science 317, 256-260 (Pubitemid 47076203)
15. Fantini, M. C., Rizzo, A., Fina, D., Caruso, R., Becker, C., Neurath, M. F., Macdonald, T. T., Pallone, F., and Monteleone, G. (2007) IL-21 regulates experimental colitis by modulating the balance between Treg and Th17 cells. Eur. J. Immunol. 37, 3155-3163 (Pubitemid 350131294)
16. Elson, C. O., Cong, Y., Weaver, C. T., Schoeb, T. R., McClanahan, T. K., Fick, R. B., and Kastelein, R. A. (2007) Monoclonal anti-interleukin 23 reverses active colitis in aTcell-mediated model in mice. Gastroenterology 132, 2359-2370 (Pubitemid 46890867)
17. Sands, B. E., Jacobson, E. W., Sylwestrowicz, T., Younes, Z., Dryden, G., Fedorak, R., and Greenbloom, S. (2010) Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease. Inflamm. Bowel Dis. 16, 1209-1218
18. Sandborn, W. J., Gasink, C., Gao, L. L., Blank, M. A., Johanns, J., Guzzo, C., Sands, B. E., Hanauer, S. B., Targan, S., Rutgeerts, P., Ghosh, S., de Villiers, W. J., Panaccione, R., Greenberg, G., Schreiber, S., Lichtiger, S., and Feagan, B. G. (2012) Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N. Engl. J. Med. 367, 1519-1528
19. Izcue, A., Coombes, J. L., and Powrie, F. (2006) Regulatory T cells suppress systemic and mucosal immune activation to control intestinal inflammation. Immunol. Rev. 212, 256-271 (Pubitemid 44116713)
20. + regulatory T cells by TGF-β induction of transcription factor Foxp3. J. Exp. Med. 198, 1875-1886
21. Volpe, E., Servant, N., Zollinger, R., Bogiatzi, S. I., Hupé, P., Barillot, E., and Soumelis, V. (2008) A critical function for transforming growth factor-β, interleukin 23 and proinflammatory cytokines in driving and modulating human T(H)-17 responses. Nat. Immunol. 9, 650-657 (Pubitemid 351712635)
22. Bettelli, E., Carrier, Y., Gao, W., Korn, T., Strom, T. B., Oukka, M., Weiner, H. L., and Kuchroo, V. K. (2006) Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441, 235-238
23. Mangan, P. R., Harrington, L. E., O'Quinn, D. B., Helms, W. S., Bullard, D. C., Elson, C. O., Hatton, R. D., Wahl, S. M., Schoeb, T. R., and Weaver, C. T. (2006) Transforming growth factor-β induces development of the T(H)17 lineage. Nature 441, 231-234
24. Veldhoen, M., Hocking, R. J., Atkins, C. J., Locksley, R. M., and Stockinger, B. (2006) TGFβ in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 24, 179-189 (Pubitemid 43214587)
25. Hirano, T., Yasukawa, K., Harada, H., Taga, T., Watanabe, Y., Matsuda, T., Kashiwamura, S., Nakajima, K., Koyama, K., and Iwamatsu, A. (1986) Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 324, 73-76 (Pubitemid 16008419)
26. Hideshima, T., Mitsiades, C., Tonon, G., Richardson, P. G., and Anderson, K. C. (2007) Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat. Rev. Cancer 7, 585-598 (Pubitemid 47106630)
27. Hibi, M., Murakami, M., Saito, M., Hirano, T., Taga, T., and Kishimoto, T. (1990) Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell 63, 1149-1157 (Pubitemid 120035064)
28. Rose-John, S., and Heinrich, P. C. (1994) Soluble receptors for cytokines and growth factors. Generation and biological function. Biochem. J. 300, 281-290 (Pubitemid 24167878)
29. +TCRlo thymocytes in vivo. Science 250, 1720-1723
30. Stephanou, A., Isenberg, D. A., Akira, S., Kishimoto, T., and Latchman, D. S. (1998) The nuclear factor interleukin-6 (NF-IL6) and signal transducer and activator of transcription-3 (STAT-3) signalling pathways cooperate to mediate the activation of the hsp90β gene by interleukin-6 but have opposite effects on its inducibility by heat shock. Biochem. J. 330, 189-195
31. Farache, J., Zigmond, E., Shakhar, G., and Jung, S. (2013) Contributions of dendritic cells and macrophages to intestinal homeostasis and immune defense. Immunol. Cell Biol. 91, 232-239
32. Hosokawa, T., Kusugami, K., Ina, K., Ando, T., Shinoda, M., Imada, A., Ohsuga, M., Sakai, T., Matsuura, T., Ito, K., and Kaneshiro, K. (1999) Interleukin-6 and soluble interleukin-6 receptor in the colonic mucosa of inflammatory bowel disease. J. Gastroenterol. Hepatol. 14, 987-996 (Pubitemid 29487295)
33. Powrie, F. (2004) Immune regulation in the intestine. A balancing act between effector and regulatory T cell responses. Ann. N.Y. Acad. Sci. 1029, 132-141
34. Siegmund, B., and Zeitz, M. (2009) Clinical aspects of inflammatory bowel disease. Eur. J. Immunol. 39, 2026-2030
35. Annunziato, F., Cosmi, L., Santarlasci, V., Maggi, L., Liotta, F., Mazzinghi, B., Parente, E., Filì, L., Ferri, S., Frosali, F., Giudici, F., Romagnani, P., Parronchi, P., Tonelli, F., Maggi, E., and Romagnani, S. (2007) Phenotypic and functional features of human Th17 cells. J. Exp. Med. 204, 1849-1861 (Pubitemid 47240944)
36. Fujino, S., Andoh, A., Bamba, S., Ogawa, A., Hata, K., Araki, Y., Bamba, T., and Fujiyama, Y. (2003) Increased expression of interleukin 17 in inflammatory bowel disease. Gut 52, 65-70 (Pubitemid 36020767)
37. + T cell-mediated lethal graft-versus-host reaction against minor histocompatibility antigen. Immunol. Lett. 136, 146-155
38. Dohi, T., and Fujihashi, K. (2006) Type 1 and 2 T helper cell-mediated colitis. Curr. Opin. Gastroenterol. 22, 651-657 (Pubitemid 44624533)
39. Leppkes, M., Becker, C., Ivanov, I. I., Hirth, S., Wirtz, S., Neufert, C., Pouly, S., Murphy, A. J., Valenzuela, D. M., Yancopoulos, G. D., Becher, B., Littman, D. R., and Neurath, M. F. (2009) RORγ-expressing Th17 cells induce murine chronic intestinal inflammation via redundant effects of IL-17A and IL-17F. Gastroenterology 136, 257-267
40. + regulatory T cells. J. Immunol. 170, 3939-3943
41. - T cells leads to rapid colitis. An improved model for pharmacologic testing. Int. Immunopharmacol. 6, 1341-1354
42. Leoni, F., Fossati, G., Lewis, E. C., Lee, J. K., Porro, G., Pagani, P., Modena, D., Moras, M. L., Pozzi, P., Reznikov, L. L., Siegmund, B., Fantuzzi, G., Dinarello, C. A., and Mascagni, P. (2005) The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol. Med. 11, 1-15
43. de Zoeten, E. F., Wang, L., Sai, H., Dillmann, W. H., and Hancock, W. W. (2010) Inhibition of HDAC9 increases T regulatory cell function and prevents colitis in mice. Gastroenterology 138, 583-594
44. Koenen, H. J., Smeets, R. L., Vink, P. M., van Rijssen, E., Boots, A. M., and Joosten, I. (2008) Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells. Blood 112, 2340-2352
45. Bosisio, D., Vulcano, M., Del Prete, A., Sironi, M., Salvi, V., Salogni, L., Riboldi, E., Leoni, F., Dinarello, C. A., Girolomoni, G., and Sozzani, S. (2008) Blocking TH17-polarizing cytokines by histone deacetylase inhibitors in vitro and in vivo. J. Leukocyte Biol. 84, 1540-1548 (Pubitemid 352774489)
46. Yang, X. O., Panopoulos, A. D., Nurieva, R., Chang, S. H., Wang, D., Watowich, S. S., and Dong, C. (2007) STAT3 regulates cytokine-mediated generation of inflammatory helper T cells. J. Biol. Chem. 282, 9358-9363 (Pubitemid 47104613)
47. Ichiyama, K., Yoshida, H., Wakabayashi, Y., Chinen, T., Saeki, K., Nakaya, M., Takaesu, G., Hori, S., Yoshimura, A., and Kobayashi, T. (2008) Foxp3 inhibits RORγt-mediated IL-17A mRNA transcription through direct interaction with RORγt. J. Biol. Chem. 283, 17003-17008
48. Jones, G. W., McLoughlin, R. M., Hammond, V. J., Parker, C. R., Williams, J. D., Malhotra, R., Scheller, J., Williams, A. S., Rose-John, S., Topley, N., and Jones, S. A. (2010) Loss of CD4+ T cell IL-6R expression during inflammation underlines a role for IL-6 trans signaling in the local maintenance of Th17 cells. J. Immunol. 184, 2130-2139
49. Mitsiades, C. S., Mitsiades, N. S., McMullan, C. J., Poulaki, V., Shringarpure, R., Hideshima, T., Akiyama, M., Chauhan, D., Munshi, N., Gu, X., Bailey, C., Joseph, M., Libermann, T. A., Richon, V. M., Marks, P. A., and Anderson, K. C. (2004) Transcriptional signature of histone deacetylase inhibition in multiple myeloma. Biological and clinical implications. Proc. Natl. Acad. Sci. U.S.A. 101, 540-545 (Pubitemid 38084672)
50. Todoerti, K., Barbui, V., Pedrini, O., Lionetti, M., Fossati, G., Mascagni, P., Rambaldi, A., Neri, A., Introna, M., Lombardi, L., and Golay, J. (2010) Pleiotropic anti-myeloma activity of ITF2357. Inhibition of interleukin-6 receptor signaling and repression of miR-19a and miR-19b. Haematologica 95, 260-269
51. Weber, D. M., Graef, T., Hussein, M., Sobecks, R. M., Schiller, G. J., Lupinacci, L., Hardwick, J. S., and Jagannath, S. (2012) Phase I trial of vorinostat combined with bortezomib for the treatment of relapsing and/or refractory multiple myeloma. Clin. Lymphoma Myeloma Leuk. 12, 319-324
52. Ito, H., Takazoe, M., Fukuda, Y., Hibi, T., Kusugami, K., Andoh, A., Matsumoto, T., Yamamura, T., Azuma, J., Nishimoto, N., Yoshizaki, K., Shimoyama, T., and Kishimoto, T. (2004)Apilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 126, 989-996 (Pubitemid 38451170)
53. Maini, R. N., Taylor, P. C., Szechinski, J., Pavelka, K., Bröll, J., Balint, G., Emery, P., Raemen, F., Petersen, J., Smolen, J., Thomson, D., Kishimoto, T., and CHARISMA Study Group (2006) Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 54, 2817-2829 (Pubitemid 44497760)